176 related articles for article (PubMed ID: 15195928)
1. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules.
Xu M; Lu X; Kallinteris NL; Wang Y; Wu S; von Hofe E; Gulfo JV; Humphreys RE; Hillman GG
Curr Opin Mol Ther; 2004 Apr; 6(2):160-5. PubMed ID: 15195928
[TBL] [Abstract][Full Text] [Related]
2. Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells.
Hillman GG; Kallinteris NL; Li J; Wang Y; Lu X; Li Y; Wu S; Wright JL; Slos P; Gulfo JV; Humphreys RE; Xu M
Gene Ther; 2003 Aug; 10(17):1512-8. PubMed ID: 12900767
[TBL] [Abstract][Full Text] [Related]
3. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.
Hillman GG; Kallinteris NL; Lu X; Wang Y; Wright JL; Li Y; Wu S; Forman JD; Gulfo JV; Humphreys RE; Xu M
Cancer Treat Rev; 2004 May; 30(3):281-90. PubMed ID: 15059651
[TBL] [Abstract][Full Text] [Related]
4. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
Humphreys RE; Hillman GG; von Hofe E; Xu M
Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
7. Presence and regulation of messenger ribonucleic acids encoding components of the class II major histocompatibility complex-associated antigen processing pathway in the bovine corpus luteum.
Cannon MJ; Davis JS; Pate JL
Reproduction; 2006 Apr; 131(4):689-98. PubMed ID: 16595720
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells.
Qiu G; Goodchild J; Humphreys RE; Xu M
Cancer Immunol Immunother; 1999 Dec; 48(9):499-506. PubMed ID: 10602887
[TBL] [Abstract][Full Text] [Related]
9. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
Bonehill A; Heirman C; Thielemans K
J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
[TBL] [Abstract][Full Text] [Related]
10. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
11. Pancreas carcinoma antigen fused to invariant chain elicits T-cell response and tumor growth inhibition.
Nagaraj S; Neumann J; Winzen B; Frank S; Ziske C; Sievers E; Koch N; Schmidt-Wolf IG
Pancreas; 2008 Oct; 37(3):321-7. PubMed ID: 18815556
[TBL] [Abstract][Full Text] [Related]
12. Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis.
Marsman M; Jordens I; Griekspoor A; Neefjes J
Adv Cancer Res; 2005; 93():129-58. PubMed ID: 15797446
[TBL] [Abstract][Full Text] [Related]
13. Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies.
Kallinteris NL; Wu S; Lu X; von Hofe E; Humphreys RE; Xu M
Vaccine; 2005 Mar; 23(17-18):2336-8. PubMed ID: 15755623
[TBL] [Abstract][Full Text] [Related]
14. Mice deficient in invariant-chain and MHC class II exhibit a normal mature B2 cell compartment.
Maehr R; Kraus M; Ploegh HL
Eur J Immunol; 2004 Aug; 34(8):2230-6. PubMed ID: 15259020
[TBL] [Abstract][Full Text] [Related]
15. Genetic modulation of tumor antigen presentation.
Xu M; Qiu G; Jiang Z; von Hofe E; Humphreys RE
Trends Biotechnol; 2000 Apr; 18(4):167-72. PubMed ID: 10740263
[TBL] [Abstract][Full Text] [Related]
16. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
[TBL] [Abstract][Full Text] [Related]
17. Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.
Rickard S; Ono SJ
Exp Mol Pathol; 2008 Dec; 85(3):147-54. PubMed ID: 18952077
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccination for cancer treatment.
Spooner RA; Deonarain MP; Epenetos AA
Gene Ther; 1995 May; 2(3):173-80. PubMed ID: 7614247
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
Fredriksen AB; Sandlie I; Bogen B
Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
[TBL] [Abstract][Full Text] [Related]
20. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
